FAST NEWS: Connect Biopharma Plunges Despite Positive Drug Trial Results
The latest: Connect Biopharma (CNTB.US) said on Tuesday its CBP-201 drug candidate achieved all primary and key secondary endpoints in the primary analysis population for a 16-week pivotal trial of…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
- TransThera seeks Hong Kong IPO to sustain cancer drug research
-
Everest reaches new heights on growing drug sales
1952.HK
